Tao Liu

List of Publications by Year in Descending Order

98 papers	12,926 citations	35 h-index	113 g-index
127 ext. papers	16,932 ext. citations	9.1 avg, IF	5.87 L-index

#	Paper	IF	Citations
98	Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells. *Theranostics*, **2021**, 11, 9605-9622	12.1	5
97	Sequencing dropout-and-batch effect normalization for single-cell mRNA profiles: a survey and comparative analysis. *Briefings in Bioinformatics*, **2021**, 22,	13.4	2
96	An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability. *Nature Communications*, **2021**, 12, 1881	17.4	8
95	A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. *Oncogene*, **2021**, 40, 2367-2381	9.2	3
94	The Emerging Roles of RNA mA Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance. *Cancer Research*, **2021**, 81, 3431-3440	10.1	20
93	The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis. *Nature Communications*, **2021**, 12, 3734	17.4	11
92	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. *Briefings in Functional Genomics*, **2021**, 20, 289-303	4.9	4
91	YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of. *Cancer Research*, **2021**, 81, 2651-2665	10.1	52
90	Targeted Therapy of -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. *Clinical Cancer Research*, **2021**, 27, 1438-1451	12.9	8
89	NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma. *Cellular and Molecular Life Sciences*, **2021**, 78, 2213-2230	10.3	7
88	The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. *Molecular Oncology*, **2021**, 15, 1162-1179	7.9	3
87	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. *Cancer Cell*, **2020**, 38, 263-278.e6	24.3	22
86	Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. *International Journal of Cancer*, **2020**, 147, 1928-1938	7.5	15
85	CPF impedes cell cycle re-entry of quiescent lung cancer cells through transcriptional suppression of FACT and c-MYC. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 2229-2239	5.6	8
84	Transcriptional regulation of G/M regulatory proteins and perturbation of G/M Cell cycle transition by a traditional Chinese medicine recipe. *Journal of Ethnopharmacology*, **2020**, 251, 112526	5	8
83	c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. *Nature Communications*, **2020**, 11, 4980	17.4	24
82	Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2

81	UVA influenced the SIRT1-miR-27a-5p-SMAD2-MMP1/COL1/BCL2 axis in human skin primary fibroblasts. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 10027-10041	5.6	1
80	The Critical Role of RNA mA Methylation in Cancer. *Cancer Research*, **2019**, 79, 1285-1292	10.1	310
79	JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. *Nature Communications*, **2019**, 10, 3319	17.4	29
78	The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. *Nature Communications*, **2019**, 10, 5026	17.4	40
77	The Histone Demethylase NO66 Induces Glioma Cell Proliferation. *Anticancer Research*, **2019**, 39, 6007-6014	2.3	4
76	Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. *Cancer Research*, **2019**, 79, 5652-5667	10.1	17
75	LncRNA REG1CP promotes tumorigenesis through an enhancer complex to recruit FANCJ helicase for REG3A transcription. *Nature Communications*, **2019**, 10, 5334	17.4	31
74	Association of GDF-15 and Syntax Score in Patient with Acute Myocardial Infarction. *Cardiovascular Therapeutics*, **2019**, 2019, 9820210	3.3	1
73	The histone chaperone complex FACT promotes proliferative switch of G cancer cells. *International Journal of Cancer*, **2019**, 145, 164-178	7.5	12
72	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. *Leukemia*, **2019**, 33, 1400-1410	10.7	20
71	Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. *Cancer Research*, **2018**, 78, 3122-3134	10.1	28
70	Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. *Cell Cycle*, **2018**, 17, 749-758	4.7	8
69	Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells. *Journal of Investigative Dermatology*, **2018**, 138, 922-932	4.3	18
68	ACTN4 regulates the stability of RIPK1 in melanoma. *Oncogene*, **2018**, 37, 4033-4045	9.2	18
67	Recognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions. *Bioinformatics*, **2018**, 34, i757-i765	7.2	22
66	A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence. *Cancer Research*, **2018**, 78, 6666-6679	10.1	16
65	The regulatory role of long noncoding RNAs in cancer. *Cancer Letters*, **2017**, 391, 12-19	9.9	75
64	The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. *Cancer Research*, **2017**, 77, 2522-2533	10.1	40

63	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. *Clinical Cancer Research*, **2017**, 23, 4462-4472	12.9	59
62	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. *Cancer Research*, **2017**, 77, 971-981	10.1	64
61	Upregulation of LYAR induces neuroblastoma cell proliferation and survival. *Cell Death and Differentiation*, **2017**, 24, 1645-1654	12.7	11
60	Chromosome preference of disease genes and vectorization for the prediction of non-coding disease genes. *Oncotarget*, **2017**, 8, 78901-78916	3.3	1
59	Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. *Cell Death and Disease*, **2016**, 7, e2252	9.8	25
58	Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia. *Leukemia*, **2016**, 30, 1745-8	10.7	7
57	High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. *Cancer Letters*, **2016**, 374, 315-23	9.9	30
56	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. *Clinical Cancer Research*, **2016**, 22, 2534-44	12.9	79
55	INPP4B is an oncogenic regulator in human colon cancer. *Oncogene*, **2016**, 35, 3049-61	9.2	40
54	Abstract 2450: MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis **2016**,		2
53	MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. *Oncotarget*, **2016**, 7, 54937-54951	3.3	12
52	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. *Oncotarget*, **2016**, 7, 79217-79232	3.3	14
51	The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. *Oncotarget*, **2016**, 7, 8663-75	3.3	88
50	NCYM is upregulated by lncUSMycN and modulates N-Myc expression. *International Journal of Oncology*, **2016**, 49, 2464-2470	4.4	15
49	IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. *Journal of Clinical Oncology*, **2015**, 33, 1285-93	2.2	33
48	Thymosin-4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. *Molecular Oncology*, **2015**, 9, 1484-500	7.9	13
47	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. *Science Translational Medicine*, **2015**, 7, 312ra176	17.5	86
46	WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. *Cancer Research*, **2015**, 75, 5143-54	10.1	52

45	Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships. *BMC Genomics*, **2015**, 16 Suppl 2, S11	4.5	15
44	An inverse relationship between serum macrophage inhibitory cytokine-1 levels and brain white matter integrity in community-dwelling older individuals. *Psychoneuroendocrinology*, **2015**, 62, 80-8	5	10
43	Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells **2015**,		2
42	The relationship of serum macrophage inhibitory cytokine-1 levels with gray matter volumes in community-dwelling older individuals. *PLoS ONE*, **2015**, 10, e0123399	3.7	14
41	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. *Oncotarget*, **2015**, 6, 39891-907	3.3	32
40	The prenatal origins of cancer. *Nature Reviews Cancer*, **2014**, 14, 277-89	31.3	153
39	Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. *Oncogene*, **2014**, 33, 2987-94	9.2	29
38	Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	81
37	Identification of plasma complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. *Journal of Proteomics*, **2014**, 96, 1-12	3.9	16
36	Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. *Oncology Reports*, **2014**, 31, 1935-9	3.5	6
35	The novel long noncoding RNA linc00467 promotes cell survival but is down-regulated by N-Myc. *PLoS ONE*, **2014**, 9, e88112	3.7	50
34	The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. *Oncotarget*, **2014**, 5, 1793-804	3.3	91
33	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. *Oncotarget*, **2014**, 5, 4257-68	3.3	24
32	Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A□via AKT in prostate cancer cells. *Oncotarget*, **2014**, 5, 6289-99	3.3	18
31	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. *Oncotarget*, **2014**, 5, 10127-39	3.3	28
30	Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. *Cell Death and Disease*, **2013**, 4, e655	9.8	30
29	The histone deacetylase SIRT2 stabilizes Myc oncoproteins. *Cell Death and Differentiation*, **2013**, 20, 503-14	9.4	141
28	Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. *Oncogene*, **2013**, 32, 3616-26	9.2	53

27	Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. *Cancer Research*, **2013**, 73, 2357-67	10.1	48
26	Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress. *Journal of Biological Chemistry*, **2013**, 288, 12032-41	5.4	7
25	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. *Nature Communications*, **2013**, 4, 1508	17.4	61
24	FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. *Leukemia*, **2013**, 27, 1053-62	10.7	29
23	Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis. *Frontiers in Genetics*, **2013**, 4, 80	4.5	53
22	Amide-based derivatives of alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. *Bioorganic and Medicinal Chemistry Letters*, **2012** , 22, 6200-4	2.9	5
21	Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. *European Journal of Cancer*, **2012**, 48, 3278-87	7.5	14
20	Neuroblastoma: A Malignancy Due to Cell Differentiation Block **2012**,		3
19	Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. *Cell Death and Disease*, **2012**, 3, e337	9.8	31
18	DOSim: an R package for similarity between diseases based on Disease Ontology. *BMC Bioinformatics*, **2011**, 12, 266	3.6	65
17	SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. *PLoS Genetics*, **2011**, 7, e1002135	6	117
16	Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. *Journal of Biological Chemistry*, **2010**, 285, 3561-3567	5.4	39
15	MYCN oncoprotein targets and their therapeutic potential. *Cancer Letters*, **2010**, 293, 144-57	9.9	75
14	The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. *Carcinogenesis*, **2009**, 30, 1865-71	4.6	16
13	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. *European Journal of Cancer*, **2009**, 45, 1846-54	7.5	37
12	The critical role of the class III histone deacetylase SIRT1 in cancer. *Cancer Research*, **2009**, 69, 1702-5	10.1	307
11	Model-based analysis of ChIP-Seq (MACS). *Genome Biology*, **2008**, 9, R137	18.3	8406
10	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. *Molecular Cancer*, **2007**, 6, 68	42.1	22

9	Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18682-7	11.5	88
8	Histone deacetylase inhibitors: multifunctional anticancer agents. *Cancer Treatment Reviews*, **2006**, 32, 157-65	14.4	193
7	The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. *Cancer Research*, **2005**, 65, 2330-6	10.1	114
6	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 3410-5	11.5	363
5	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. *Lancet, The*, **2002**, 359, 2159-63	40	198
4	ATP P2X receptors play little role in the maintenance of neuropathic hyperalgesia. *NeuroReport*, **2000**, 11, 1669-72	1.7	17
3	Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. *Pain*, **2000**, 86, 25-32	8	180
2	Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. *Pain*, **1999**, 79, 31-37	8	104
1	Zinc alleviates thermal hyperalgesia due to partial nerve injury. *NeuroReport*, **1999**, 10, 1619-23	1.7	14